89bio to Participate in the H.C. Wainwright 23rd Annual Global Investment Conference
89bio, Inc. (Nasdaq: ETNB) announced its participation in the H.C.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
89bio, Inc. (Nasdaq: ETNB) announced its participation in the H.C. Wainwright 23rd Annual Global Investment Conference from September 13-15, 2021. The presentation will be available on-demand starting September 13 at 7:00 a.m. ET via the H.C. Wainwright conference portal. An archived webcast will be accessible on 89bio’s website. 89bio focuses on innovative therapies for liver and cardio-metabolic diseases, with its lead product candidate, BIO89-100, targeting nonalcoholic steatohepatitis and severe hypertriglyceridemia.
Details
News Market Reaction – ETNB
The recorded move for ETNB in the trading session of this news was +0.26%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
SAN FRANCISCO, Sept. 08, 2021 (GLOBE NEWSWIRE) -- 89bio, Inc. (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardio-metabolic diseases, today announced that Company’s Management will participate in the H.C. Wainwright 23rd Annual Global Investment Conference to be held September 13-15, 2021.
The presentation will be available on-demand through the H.C. Wainwright conference portal, starting at 7:00 a.m. ET on Monday, September 13, 2021. An archived webcast will also be accessible in the investor section of 89bio’s website.
About 89bio
89bio is a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardio-metabolic diseases. The company’s lead product candidate, BIO89-100, is a specifically engineered glycoPEGylated analog of FGF21. BIO89-100 is being developed for the treatment of nonalcoholic steatohepatitis (NASH) and severe hypertriglyceridemia (SHTG). 89bio is headquartered in San Francisco with operations in Herzliya, Israel.
Investor Contact:
Ryan Martins
Chief Financial Officer
investors@89bio.com
Media Contact:
Peter Duckler
773-343-3069
pduckler@w2ogroup.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.